As a large, comprehensive and modernized pharmaceutical enterprise in China, Qilu Pharmaceutical Group specializes in research, manufacture and marketing of finished products and active pharmaceutical ingredients for the treatment of oncological, cardiovascular and cerebrovascular, infectious, psychological, neurological and ophthalmic diseases. Covering a total area of 575 hectares, Qilu is equipped with 10 major manufacturing sites, 12 subsidiaries and a total number of over 30,000 employees by far, meanwhile, besides human use drugs, Qilu’s business coverage also includes R&D, manufacture and marketing of APIs and finished products of animal use chemical drugs, animal use biologics, biological agricultural drugs. In 2020, sales revenue of the Group reached 4.2 billion US dollars, with an export revenue of 700 million US dollars and a tax contribution of 288 million US dollars, Qilu has been ranking among top 10 on the list of the top 100 best performing units in the Chinese pharmaceutical industry for many consecutive years.

Constantly adhering to an innovation-driven strategy, Qilu managed to first or exclusively launch over 48 drug products in China, covering human use drugs, agricultural and animal use drugs, with 5 drug products awarded with National Technological Progress Second Prizes.  With 91 products passing the quality consistency evaluation, among which 38 were first to pass in China, Qilu is a double winner in the field of quality consistency evaluation.

In terms of intellectual property, Qilu has made over 598 patent applications, among which 443 has been granted; with 14 PCT applications received 24 grants in the US, EU, Canada, Japan, Korea, Australia and so on, Qilu is also the MA holder of multiple finished drug products launched in the US through patent challenging. Keeping in step with the international trend of innovative drug development and integrating global high quality resources to develop First in Class and Best in Class therapeutics, Qilu has established 5 major innovative R&D platforms linking China and the US, consecutively developing high quality innovative drugs in the global picture. To meet unmet and major medical needs, Qilu has designed a comprehensive innovative drug pipeline in the therapeutic areas of oncological, infectious, hepatic, autoimmune, metabolic diseases and so on, aiming to launch 10 to 12 innovative drugs to the market in the next 5 years.

Developing drug products with best quality and safety profiles is the firm commitment of Qilu team. Equipped with an internationalized quality management system, Qilu is the first enterprise certified by FDA, EDQM and MHRA for sterile products in China. With a scientifically-designed and comprehensive product structure, Qilu products is strictly serialized and cover a wide range of therapeutic areas, and has been exported to over 80 countries and regions all over the world, among which 12 human use APIs in cephalosporin and tazobactam family takes up the largest market share globally. Qilu Group is the only Chinese domestic company exporting finished products to regulated markets including EU, US, UK, Japan and Australia, with 18 products taking up the largest local market share, Qilu is also the first Chinese company to export commercially packed injectable products to Japan, currently, the Group has exported 17 finished products to the US, 10 products to the EU, while its cephalosporin finished products taking up the largest market share in Australia.